GL1X · GenesisL1 explorer

MolNFT v1 · #138922 · protein

Crystal structure of human TLR8 in complex with cu-CPT8M

5WYX · Toll-like receptor 8: “Crystal structure of human TLR8 in complex with cu-CPT8M”. X-ray diffraction, 4 ligands (CU8, NAG, MAN), 10 pockets (best druggability 0.80). MolNFT v1 #138922 on GenesisL1: 3D structure, binding sites and…

PDB
5WYX
Type
protein
Length
1,489 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Toll-like receptor 8
UniProt
Q9NR97
Ligands
CU8, NAG, MAN, BMA
Pockets
10 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 10% helix, 16% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AToll-like receptor 8protein75010% helix, 16% strandQ9NR97
BToll-like receptor 8protein73911% helix, 16% strandQ9NR97

Ligands and binding sites

  • CU8 · 7-(3-methylphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide · ligand · 2 copies · chains A, B
  • NAG · 2-acetamido-2-deoxy-beta-D-glucopyranose · sugar · 18 copies · chains A, B
  • MAN · alpha-D-mannopyranose · sugar · 5 copies · chains A
  • BMA · beta-D-mannopyranose · sugar · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

10 pockets found on a 1 Å grid, 8 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
19740.800.82115NAG, CU8
29230.780.8088CU8
34560.660.7865NAG
43430.600.7743NAG
53950.580.7428empty

Interfaces

1 interface between chains.

  • A–B · 1510 Ų buried · 8 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 12 disulfide, 12 glycan (disulfide, N-glycosylation).

Compared structures

  • 5WYX · Crystal structure of human TLR8 in complex with CU-CPT8m · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.